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Background: Our previous work demonstrated that persistent peripheral nociception (PPN) leads to synaptic
plasticity and functional changes in the rat hippocampus. The protein kinase mTOR is a critical regulator of protein
synthesis-dependent synaptic plasticity in the hippocampus as well as synaptic plasticity associated with central
and peripheral pain sensitization. We examined the role of mTOR signaling in pain-associated entorhinal cortex
(EC) − hippocampal synaptic plasticity to reveal possible cellular mechanisms underlying the effects of chronic
pain on cognition and emotion.
Results: Subcutaneous injection of bee venom (BV) into one hind paw to induce PPN resulted in sustained
(> 8 h) mTOR phospho-activation and enhanced phosphorylation of the mTOR target p70 S6 kinase (S6K) in the
hippocampus. The magnitude and duration of long-term potentiation (LTP) in both EC − dentate gyrus (DG) and
EC − CA1 synaptic pathways were elevated in BV-treated rats as measured by microelectrode array recording.
Moreover, the number of potentiated synapses in the hippocampus was markedly upregulated by BV-induced PPN.
Both elevated mTOR-S6K signaling and enhanced LTP induced by BV injection were reversed by systemic injection
of the mTOR inhibitor rapamycin (RAPA). Rats injected with BV exhibited markedly reduced ambulation and
exploratory activity in the open field (signs of depression and anxiety) compared to controls, and these effects
were also reversed by RAPA.
Conclusion: We suggest that PPN-induced enhancement of synaptic plasticity in EC − hippocampal pathways
and the behavioral effects of PPN are dependent on mTOR-S6K signaling.
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Pain is a complex sensory modality involved in sensory
discrimination, affective motivation, and cognitive eva-
luation [1]. As a homeostatic mechanism, nociception
serves to protect against injury. However, persistent
nociceptive stimuli may develop into chronic pain, a
neurological condition that greatly reduces quality of life.
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reproduction in any medium, provided the orpathways from the spinal cord to many regions of the
brain involved not only in sensory perception but also in
emotion and cognition. Thus, chronic pain can disrupt
many higher brain functions and lead to cognitive disor-
ders and mental illness.
Sensitization of primary sensory neurons and altered
synaptic plasticity in the spinal dorsal horn contribute to
chronic pain [2,3]. In contrast, the effects of chronic
nociceptive input on the structure and function of
higher brain structures are still largely unexplored,
greatly impeding progress in clinical pain management
and development of more efficacious analgesics and
other pain therapies. Revealing the cellular and mole-
cular signaling mechanisms mediating the effects of. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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will improve our understanding of chronic pain deve-
lopment and provide insight into therapeutic strategies
for relieving the negative emotional responses to chronic
pain [4].
Chronic pain alters synaptic transmission in the cere-
bral cortex and limbic system [5,6]. The hippocampal
formation is an integral part of the Papez circuit invol-
ved in learning, memory, emotion, and motivation [7].
Functional magnetic resonance imaging, electrophysio-
logical, and neurochemical studies have demonstrated
that formalin-induced nociception can alter hippocam-
pal neuron activity, as well as the expression and activa-
tion of proteins in these neurons [8]. Intrahippocampal
injection of NMDA receptor antagonists [9] attenuates
these changes, strongly implicating hippocampal pro-
cessing of nociceptive information in the deleterious
effects of chronic pain on cognitive, emotional, and
motivational functions [8]. Nonetheless, the impacts of
chronic pain on hippocampal structure and function are
still rarely examined.
Target of rapamycin (TOR) was first described in
TOR1 and TOR2 Saccharomyces cerevisiae mutants
[10]. The TOR1 and TOR2 genes encode homologous
(60%) TOR1 and TOR2 proteins of 280 kDa. The
highly conserved mammalian homologue mTOR is a
member of the phosphoinositide 3-kinase related kin-
ase (PIKK) family of serine/threonine kinases [11].
Rapamycin is a lipophilic antibiotic isolated from a
strain of Streptomyces hygroscopicus indigenous to
Easter Island (Rapa Nui) that is currently used as an
immunosuppressive drug [12]. The eukaryotic rapa-
mycin receptor is the 12 kDa FK506-binding protein
12 (FKBP12). A rapamycin-FKBP12 “gain-of-function”
complex interacts specifically with mTOR to potently
inhibit signaling to downstream targets [13]. The
mTOR signaling pathway regulates transcription, initi-
ation of translation, ribosome biosynthesis, and apop-
tosis in response to multiple activating factors [14].
However, whether the mTOR signaling pathway is
involved in the regulation of pain and hyperalgesia is
unresolved.
Recent studies demonstrated that mTOR regulates
cell growth, proliferation, and synaptic plasticity by
activating protein synthesis [14]. Many downstream
mTOR effector proteins are crucial for translation, in-
cluding eIF4E binding protein-1 (4EBP1), ribosomal
protein S6 kinase (p70S6K), and eukaryotic elongation
factor 2 (eEF2) [15]. To regulate cell growth and
proliferation, mTOR phosphorylates 4EBP1 and S6K
to initiate translation. Phosphorylation of eEF2, a pro-
tein regulating polypeptide elongation and ribosomal
translocation, is indirectly regulated by mTOR. Rapa-
mycin blocks long-term potentiation (LTP) in the rathippocampus induced by either tetanic stimulation or
BDNF [16]. Medina et al. also demonstrated that mTOR
signaling participates in hippocampus-dependent long-
term memory consolidation [17]. It is established that
long-lasting synaptic plasticity, neurite development, and
response to injury are regulated by local protein synthesis
in axons and dendrites [18], which contain all necessary
components for local protein synthesis, including mRNAs
and ribosomes [19]. The contribution of mTOR signaling
to local protein synthesis is currently a major research
focus. Jimenez-Diaz et al. reported that mTOR-dependent
local mRNA translation maintained hyperalgesia mediated
by A-fiber nociceptors [20]. In addition, mTOR partici-
pates in central and peripheral nociceptive sensitization
[21]. Recently, Asante et al. revealed a role for mTOR in
persistent pain maintenance mediated by mRNA trans-
lation and local protein synthesis following formalin-
induced nociception [22].
Here, we used bee venom (BV) injection, a reliable
model of persistent peripheral nociception (PPN)
[23], to investigate the role of mTOR in structural
and functional changes in the hippocampus induced
by pain. We examined molecules activated by the
mTOR signaling pathway, the effect of mTOR signal-
ing on synaptic plasticity at DG and CA1 synapses,
and the effects PPN-induced mTOR activation on
behavior.
Results
Persistent peripheral nociceptive stimuli activated the
mTOR signaling pathway in rat hippocampus
The phosphorylation status of mTOR and its down-
stream signaling molecule S6K were significantly ele-
vated in the hippocampus 2 h after BV injection, and
phosphorylation was maintained for at least 8 h post-
injection compared to the control group (p-mTOR-
BV/p-mTOR-NS: 1.87 ± 0.21 at 2 h, 1.90 ± 0.34 at 4 h,
1.86 ± 0.20 at 8 h; all P < 0.05 vs. control group;
p-S6K-BV/p-S6K-NS: 1.52 ± 0.05, 1.53 ± 0.14, and 1.40 ±
0.07; all P < 0.05 vs. control group) (Figure 1A). In
contrast, relative expression levels of total mTOR and S6K
were not significantly changed. These elevations in mTOR
and S6K phosphorylation were reversed when BV
injection was preceded by bupivacaine (Bup, Figure 1B)
or rapamycin (RAPA, Figure 1C). The relative levels
of p-mTOR and p-S6K were significantly reduced by
bupivacaine pretreatment compared to matched controls
(Sal + BV groups) (p-mTOR: 1.10 ± 0.05 vs. 1.38 ± 0.12,
P < 0.05; p-S6K: 0.87 ± 0.08 vs. 1.39 ± 0.13, P < 0.01).
Similarly, rapamycin pretreatment reduced relative
p-mTOR and p-S6K expression levels compared to
2% DMSO + BV controls (p-mTOR: 0.82 ± 0.11 vs.
1.32 ± 0.04, P < 0.01; p-S6K: 0.86 ± 0.13 vs. 1.53 ± 0.19,
P < 0.05).
Figure 1 Activation of the mTOR signaling pathway in the hippocampus by persistent peripheral nociception, but the effect was
reversed by rapamycin (RAPA). (A) Western blot analysis of p-mTOR, mTOR, p-S6K, and S6K expression in hippocampal lysates at various times
after bee venom (BV) treatment. (B) Western analysis of p-mTOR, mTOR, p-S6K, and S6K in hippocampus tissues extracts from saline control
(sal-control), Sal + BV, and bupivacaine (Bup) + BV groups. (C) Western blot analysis of p-mTOR, mTOR, p-S6K, and S6K in hippocampal lysates
from Sal-control, 2%DMSO + BV, and RAPA + BV groups. Relative expresions of p-mTOR, mTOR, p-S6K, and S6K immunolabeling are shown
relative to the control or sal-control (100%). β-tubulin was used as an internal control. The data were showed as means ± SD (n = 3). *P < 0.05 vs.
sal-control group; #P < 0.05, ##P < 0.01, bupivacaine + BV group vs. Sal + BV; ΔP < 0.05, ΔΔP < 0.01, RAPA + BV group vs. 2%DMSO + BV group.
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synaptic plasticity induced by persistent peripheral
nociceptive stimuli
The basal strength of excitatory transmission and LTP
induced by theta-burst stimulation (TBS) were measured
using a 8 × 8 MED array in response to perforant path-
way (PP) stimulation at the hippocampal sulcus. Two
types of potentials were recorded, a positive inflection in
the DG and a negative inflection from the CA1. Many
hippocampal excitatory pathways exhibit robust and
stable LTP. Three stimulus protocols are commonly
used to induce LTP, high-frequency stimulation (HFS),TBS, and primed burst stimulation. We chose TBS as it
partially replicates the stimulus pattern of the naturally
occurring theta rhythm recorded in the hippocampus
in vivo during learning and memory [24].
The sites of PP stimulation and recordings by the
MED-64 array are shown for a naïve group rat slice
(Figure 2A), 2%DMSO + BV group rat slice (Figure 2D),
and RAPA + BV group rat slice (Figure 2G). Typical
sample fEPSPs evoked at 50% of maximum amplitude
from the DG (negative inflections) before TBS, 60 min
post-TBS, and 120 min post-TBS are superimposed
(Figure 2B, naïve; Figure 2E, 2%DMSO + BV; Figure 2H,
Figure 2 Multichannel recording of field excitatory
postsynaptic potentials (fEPSPs) in hippocampal slices from 2%
DMSO + BV and RAPA + BV groups before and after theta burst
stimulation. (A-C) Responses from a naive group rat (A)
Photograph showing the hippocampal formation from a naïve
group rat and Med-64 probe with 8 × 8 array. The asterisk indicates
an electrode selected for electrical stimulation of the perforant path
(PP) fibers. Real traces of 63 recording electrodes across the DG and
the CA1 area in response to perforant path (PP) test stimulation
before (black), 60 min after (green), and 120 min (red) after TBS. The
PP-evoked network FP responses were localized in both the DG and
CA1. (B) fEPSPs are negative-going (lower) in CA1. (C) fEPSPs are
positive-going (upper) in the DG. fEPSP amplitudes in these two
areas were potentiated by TBS stimulation of PP fibers (asterisk).
Scale bar applies to both sweep sets. (D-F) Micrograph of a
hippocampal slice and evoked responses from a 2%DMSO + BV
group rat. (G-I) Hippocampal slices and typical sample recordings
from a RAPA+ BV-treated rat. (J and K) Summary of LTP experiments
in hippocampal slices from naive, 2%DMSO + BV and RAPA+ BV
groups. The amplitude of both the DG (J) and CA1 (K) fEPSPs was
normalized to pre-TBS baseline. The data were showed as means ± SD
(n = 7). *P < 0.05, RAPA + BV group vs. 2%DMSO + BV group.
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(positive inflections) evoked at 50% of maximum ampli-
tude are also shown (Figure 2C, F, and I, respectively),
The post-TBS fEPSPs were significantly larger in the 2%
DMSO + BV group compared to the naïve group and the
RAPA + BV group in both DG and CA1, and LTP in
both pathways lasted for more than 2 hours in the 2%
DMSO + BV group. The time course of LTP for the
different treatment groups is summarized in Figure 2J
(DG) and Figure 2K (CA1). At 2 h post-TBS, the
normalized mean fEPSP amplitude in the DG was sig-
nificantly greater in the 2%DMSO + BV group than in
the RAPA + BV group (161.09 ± 4.60% vs. 127.87 ±
2.14%, n = 6 for both groups, Figure 2J). Similarly, mean
LTP amplitude in the CA1 at 2 h post-TBS was sig-
nificantly larger in the 2%DMSO + BV group than in
the RAPA + BV group (190.56 ± 14.00% vs. 130.77 ± 9.32%,
n = 6 for the 2%DMSO+ BV group and n = 7 for the
RAPA + BV group, Figure 2K). Moreover, mean DG and
CA1 LTP amplaitudes in RAPA + BV group slices were
not significantly different from naïve rat slices, indicating
complete reversal of the pain-mediated LTP enhancement.
The amplitude of LTP started to decrease 80 min (DG)
and 90 min (CA1) after TBS in the RAPA + BV group,
while the magnitude continued to increase for the entire
2 h recording period in the vehicle-treated group.
mTOR signaling regulated the spatial extent of synaptic
plasticity induced by persistent peripheral nociceptive
stimuli
The number of channels in which the mean fEPSP
induced by stimulus pulses from 30 to 199 μA was > 20%
of the baseline fEPSP amplitude at the channel chosen to
record LTP (Figure 3A) was used as an index of the spatial
Figure 3 Spatial distribution of pain-potentiated synapses in hippocampal slices from naive, 2%DMSO + BV and RAPA + BV groups. (A)
Averaged number of fEPSPs reliably evoked at >20% baseline (“large” fEPSPs) across the 8 × 8 array with increasing stimulus intensity. Compared
to the 2%DMSO + BV group, the number of large fEPSPs in the RAPA + BV treated group was significant lower at each suprathreshold stimulus
applied (30 − 199 μA). (B) Stimulus intensity-network response function curves in slices from 2%DMSO + BV and RAPA + BV groups. Individual
fEPSP in DG (upper) and CA1 (lower) area increased in amplitude (a, b) or slope (c, d) at greater stimulus intensity. The input-output (I-O) function
curves of the hippocampal network response were right-shifted in the RAPA + BV treatment group compared to the 2%DMSO + BV treatment
group. The data were showed as means ± SD (n = 8). *P < 0.05, **P < 0.01 RAPA + BV group vs. 2%DMSO + BV group.
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lus intensity-network response function curves for both
DG and CA1 are presented in Figure 3A, and input/out-
put curves (amplitude and slope of fEPSPs against stimu-
lus intensity) for both DG and CA1 recording sites are
shown in Figure 3B. The amplitudes of the DG and CA1
potentials increased as stimulus intensity increased, and
the fEPSP slope in DG and CA1 displayed a linear
relationship with increasing stimulus intensity. Compared
to the 2%DMSO+ BV group, the stimulus intensity-
network response function curve of the naïve and RAPA
+ BV groups exhibited a shallower rise (Figure 3A, B). In
other words, the number of channels in which fEPSP
amplitude was > 20% of the principal response channel
baseline was lower in naïve and RAPA + BV group rats
than 2%DMSO+ BV group rats at the same stimulus in-
tensity, suggesting a more restricted spatial distribution of
strong pain-induced synaptic potentiation (30 μA: 9.63 ±
0.56 vs. 14.50 ± 0.56, 60 μA: 12.38 ± 0.75 vs. 19.00 ± 1.21,
90 μA: 14.88 ± 0.83 vs. 23.67 ± 1.15, 120 μA: 17.38 ± 0.68
vs. 27.50 ± 1.18, 150 μA: 19.25 ± 0.59 vs. 30.83 ± 0.60,
180 μA: 20.38 ± 0.73 vs. 33.33 ± 0.67, 199 μA: 21.00 ± 0.85
vs. 34.00 ± 0.68; n = 6 for all). Our results indicate thatrapamycin inhibits the tendency for chronic pain to
enhance glutamatergic synaptic transmission over a broad
area of the hippocampus. Conversely, unsuppressed chro-
nic pain may increase the mean activation area of the
hippocampus in response to a given EC input.
mTOR signaling regulated changes in spontaneous
locomotor activity induced by persistent peripheral
nociceptive stimuli
Changes in spontaneous locomotor activity were assessed
in the open field (OF). The hippocampal formation is an
integral part of the Papez circuit that regulates emotion
and motivation, so changes in synaptic strength and plasti-
city may alter spontaneous activity. Parameters recorded
in the OF for the naïve group, 2%DMSO+ BV group, and
RAPA + BV group were trajectory (Figure 4), total distance
travelled, distance travelled in the central, peripheral, and
corner zones, number of hole explorations, average speed,
activity counts, and duration of activity (all in Figure 5).
Movement diminished with time for all three groups, but
2%DMSO+ BV group rats exhibited the shortest total
distance travelled during 1 h in the OF. These rats often
remained at a fixed point in one of the OF corners for
Figure 4 Locomotion tracks in the open field (OF) were recorded in 10-min blocks and the preferred place data collected over 1 hour.
Locomotion decreased in all groups (naive group without any treatment; RAPA + BV group; 2%DMSO + BV group) over 1 hour, but was lowest in
the 2%DMSO + BV group.
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tral and peripheral regions to total distance travelled were
significantly lower in the 2%DMSO+ BV group, while the
ratio of total distance in the four corner regions to total
distance travelled was higher in the 2%DMSO+ BV group
(Figure 4). Thus, 2%DMSO+ BV-treated rats exhibited
reduced ambulation, a behavioral endophenotype of de-
pression. Moreover, increased time spent in the corners is
indicative of greater anxiety in 2%DMSO+ BV rats. These
signs of depression and anxiety were reversed by RAPA
pretreatment. Finally, the number of hole explorations,
average speed, number of mobility events, and the
duration of these events were all significantly lower in 2%
DMSO+ BV group rats compared to naïve and RAPA +
BV group rats (Figure 5). Based on the reversal of these
effects by RAPA, we suggest that mTOR signaling is
involved in the emotional response of rats to PPN.
Discussion
In 1937, Papez proposed that the limbic system was the
anatomic region underlying emotion (and so is often
called the Papez circuit). The hippocampus and associ-
ated structures of the medial temporal lobe are integralparts of the Papez circuit and critical structures for
learning and memory [25,26]. Recent evidence also
supports the involvement of the hippocampus and EC in
pain processing [27]. Melzack and Casey suggested in
1968 that the limbic system, including the hippocampus,
plays a vital role in the formation of motivational drive
and negative emotional responses to pain [15], but the
precise cellular and molecular mechanisms have remained
elusive. Previous work from our laboratory demonstrated
altered temporal synaptic plasticity and transmission in
EC − hippocampal pathways induced by persistent peri-
pheral nociceptive stimuli [28], and the current study
implicates hippocampal mTOR signaling in both altered
hippocampal plasticity and the behavioral responses to
persistent pain.
Dendritic protein synthesis is critical for long-lasting
synaptic modifications [29], and mTOR is thought to
modulate the local translation of mRNAs via the phos-
phorylation of several downstream translation effector
proteins, including S6K1 and 4EBP1 [30]. Phosphorylation
of S6K1 mediates translation initiation and polypeptide
elongation, while 4EBP1 is a repressor of eukaryotic initi-
ation factor 4E (eIF4E). Interaction of 4EBP1 with eIF4E
Figure 5 The total distance and region-specific distances traveled in the OF by naive, 2%DMSO + BV, and RAPA + BV groups. (A) The
total distance travelled in the OF after 10, 20, 30, 40, 50 and 60 min. (B) The total distance over an entire hour. (C) The fold of distance traveled in
the center, corner, or side regions of the OF to the total distance traveled (an index of place preference) for naive, 2%DMSO + BV, and RAPA + BV
groups. (D − G) Differences in (D) number of hole explorations, (E) average speed, (F) number of locomotor events, and (G) time spent in
locomotion for naive, 2%DMSO + BV, and RAPA + BV groups. The data were showed as means ± SD (n = 10). *P < 0.05, **P < 0.01 vs. naïve group;
#P < 0.05, ##P < 0.01 RAPA + BV group vs. 2%DMSO + BV group.
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[30]. Activation of mTOR signaling by postsynaptic recep-
tors and ion channels [31,32] induces the dendritic protein
synthesis required to maintain long-lasting forms of
synaptic plasticity, particularly late-LTP (L-LTP). This
study suggests that persistent peripheral pain also activates
the mTOR pathway in hippocampal dendrites, thereby
lowering the threshold or increasing the strength of TBS-
induced L-LTP.
There are two behaviorally relevant aspects of synaptic
plasticity, changes in strength over time and the spatial
distribution of these changes. Hippocampal LTP is a
form of activity-dependent synaptic plasticity widely
studied as a cellular model of associative learning, most
notably at EC −DG granule cell synapses and EC − CA1
pyramidal cell synapses [33]. Theoretically, enhanced
synaptic strength could result from greater presynaptic
glutamate release (through release of greater numbers of
quanta per bouton or the recruitment of greater num-
bers of presynaptic axons) or an enhanced postsynaptic
response to the same level of glutamate release. These
opposing mechanisms have been debated for several
decades [33].
In contrast, the spatial distribution of these changes in
synaptic strength has been studied less extensively. Here,
we explored these changes during persistent peripheralnociceptive stimuli using a planar microelectrode array.
Previous work has successfully applied the MED64
probe (Panasonic, Japan) to multiple brain regions re-
sponsible for nociception [28] and confirmed its stability
and reliability [34]. Persistent peripheral nociceptive
stimuli can alter both spatial and temporal plasticity in
the EC − hippocampal pathway [28]. Given that the
mTOR signaling pathway is activated by PPN and is a
known regulator of LTP, we examined the effects of
mTOR inhibition on both temporal and spatial changes
in synaptic strength at EC −DG and EC −CA1 synapses
simultaneously using the MED 8 × 8 grid. The normal-
ized fEPSP amplitude and LTP amplitude 2 h post-TBS
(L-LTP) were significantly lower in RAPA-pretreated,
BV-injected rats compared to BV-injected rats pretreated
with the vehicle DMSO (2%DMSO + BV group). The
maintenance of LTP is dependent on protein synthesis
[35,36], and mTOR signaling is involved in local protein
synthesis required for the maintenance of LTP at both
EC −DG and EC −CA1 synapses. Here we show that
pain-dependent mTOR activation in the hippocampus
induces widespread changes in synaptic strength. In
contrast to the localized changes in synaptic strength
responsible for associative learning, this broadly distrib-
uted LTP may disrupt learning and other hippocampal
functions.
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forms of spatial synaptic plasticity, enhanced presynaptic
release, probably by recruiting additional presynaptic
fibers, and enlargement of the responsive hippocampal
network, possibly due to formation of new synapses [28].
Input/output curves and stimulus intensity-network re-
sponse functional curves were right-shifted in RAPA-
treated, BV-injected rats compared to the 2%DMSO+ BV
group (Figure 3), indicating fewer potentiated synapses
within the recording array. Synapse formation and struc-
tural alterations in dendritic spines associated with LTP
are dependent on local protein synthesis [29,35,36]. In
addition, systemic inhibition of mTOR blocks hyperalgesia
in animal models of neuropathic pain [37-39], We suggest
that mTOR-mediated local protein synthesis participates
in enhancing synaptic strength and synaptogenesis to
enlarge the hippocampal neural network responsive to
nociceptive inputs. Taken together, mTOR signaling likely
plays an important role in spatiotemporal plasticity in
EC − hippocampal pathways during persistent peripheral
nociceptive stimuli.
Spontaneous activity in the open field test is used to
evaluate the characteristics of affective disorders induced
by chronic pain, such as anxiety and depression [40,41].
Spontaneous activity, including both locomotion and
exploratory behavior, was abated after injecting BV into
the plantar surface of left hind paw, and these behavioral
signs of anxiety and depression were reversed by rapa-
mycin pretreatment. Thus, hippocampal mTOR sig-
naling is likely involved in both the synaptoplastic
and behavioral responses to PPN, although more
specific tests of the behavioral endophenotypes of
depression and anxiety are needed to strengthen this
association.
Given that rapamycin was administered systemically,
we cannot exclude the contribution of PPN-induced and
mTOR-dependent synaptic plasticity in other brain
regions to these behavioral changes. Indeed, synapto-
plastic changes or neural disinhibition in the thalamus,
somatosensory cortex, amygdala, insula, and (or) cingu-
late cortex may also contribute [42,43]. However, it
should be noted that intracerebral or intrahippocampal
injection can damage local circuits and will result in a
sizeable drug concentration gradient, with possible non-
specific effects due to excess rapamycin near the electrode
tip and insufficient LTP blockade at distant synapses.
Furthermore, our in vitro studies indicate that mTOR
inhibition markedly reduces L-LTP in the hippocampus,
and many studies implicate the hippocampus in pain
processing [5,6,16,28].
Conclusions
Persistent peripheral pain triggered prolonged activation
of the mTOR signaling pathway in the hippocampus asevidenced by mTOR and S6K phosphorylation, and this
response was ameliorated by rapamycin pretreatment.
Rats subjected to PPN demonstrated enhanced and
more widespread LTP in EC −DG and EC −CA1 path-
ways, and these effects were also reversed by rapamycin.
Finally, rats subjected to PPN showed behavioral signs of
depression and anxiety, responses which again were
reversed by rapamycin. Collectively, these results strongly
suggest that activation of mTOR by PPN induces dendritic
protein synthesis, which in turn enhances long-lasting
LTP nonspecifically and broadly throughout EC − hippo-
campal networks. These synaptoplastic changes alter
rat behavior, although the scope of these behavioral
changes and the underlying mechanisms remain to be
determined.Methods
Animals
Adult male Sprague-Dawley rats (body weight 180 −
240 g, age 6 − 8 weeks) were obtained from the Experi-
mental Animal Center of the Fourth Military Medical
University (Xi’an, China) and housed with ad libitum
access to food and water under a 12:12 h light/dark cycle
at 22 − 26°C and 50 ± 5% humidity. All procedures and
animal experiments were approved by the animal Ethical
Committee of the Fourth Military Medical University and
all procedures were in accordance with the International
Association for the Study of Pain (IASP) guidelines [44].Study design
A control group of rats received no treatment and
are referred to as the naive group. In experimental
rats, the mid-plantar surface of the left hind paw was
subcutaneously injected with normal saline (NS, CON) or
bee venom (BV) (0.2 mg in 50 μl NS, Sigma, MO, USA)
[45]. To evaluate the analgesic effects of bupivacaine and
rapamycin against BV injection, four other groups of rats
were treated as described below. Bupivacaine (0.25%,
600 μl; Shanghai Harvest Pharmaceutical Co., Ltd., China)
or an equal volume of NS was injected into the ankle of
the left hind paw 10 min before BV administration, and
BV was allowed to activate nociceptive afferents for 2 h
(Bup + BV group and Sal + BV group). For rapamycin
(RAPA) (Chengdu YATU biotechnology CO., LTD., China)
treatment and matched RAPA control groups, rats re-
ceived either 2%DMSO (Sigma, MO, USA) or RAPA
(10 mg/kg RAPA in 2%DMSO) by gavage for 3 days
(1 ml/d), followed 1 h after the last gavage administration
by BV injection to the plantar surface of the left hind paw
(2%DMSO+ BV and RAPA + BV groups). In a subgroup
of these rats, brains were collected 0.5, 1, 2, 4, and 8 h
after injection for LTP experiments and Western blotting
as described below.
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Rats were sacrificed by decapitation at various times
after drug treatment. The hippocampus was quickly
dissected from the brain, immersed in liquid nitrogen
for frozen grinding, and lysed in ice-cold RIPA lysis
buffer (Beyotime, Jiangsu, China). Homogenates were
then centrifuged at 12000 × g for 10 min at 4°C and a
supernatant sample retained to measure total sample
protein concentration using a BCA protein assay kit
(Thermo, IL, USA). The remaining supernatant samples
were stored at -70°C until use.
Equal amounts of protein (30 μg) were applied to each
gel lane, separated by 8% SDS-PAGE, and electrotrans-
ferred to nitrocellulose membranes (Millipore, MA,
USA). Membranes were blocked with 5% milk powder
(Bio-rad, CA, USA) in PBS with 0.05% Tween 20 (PBST)
for 1 h at room temperature (RT), then incubated over-
night at 4°C in PBST containing rabbit anti-mTOR
(1:1000, Cell Signaling Technology, MA, USA), rabbit
anti-p-mTOR (1:500, Cell Signaling Technology), rabbit
anti-S6K (1:500, Cell Signaling Technology), rabbit anti-
p-S6K (1:500, Cell Signaling Technology), and mouse
anti-β-tubulin (1:10000, Sigma, MO, USA). Membranes
were then washed three times (10 min/wash) with PBST
and incubated for 1 h at RT with a horseradish peroxid-
ase (HRP)-conjugated goat anti-rabbit IgG (1:5000,
ZSGB-BIO, Beijing, China) and goat anti-mouse IgG
(1:5000, ZSGB-BIO). The membranes were washed four
times with PBST (10 min/wash). Immunolabeling was
visualized by ECL solution (Pierce, IL, USA) and photo-
graphed by a gel image analysis system (Alpha Innotech,
USA). Intensities were measured by FluorChem II
software and relative intensities of target bands were
analyzed and normalized to β-tubulin intensity.
Planar microelectrode array recording
Rats were deeply anesthetized by intraperitoneal injec-
tion of pentobarbital sodium (40 mg/kg, Sigma) 2 h after
BV administration and sacrificed by decapitation. The
whole brain was carefully removed using Rongeurs and a
spatula, and submerged in ice-cold artificial cerebro-
spinal fluid (aCSF containing in g/l: 6.838 NaCl, 0.268
KCl, 2.1 NaHCO3, 0.187 NaH2PO4 · 2H2O, 0.278 CaCl2,
0.244 MgCl2 · 6H2O, 1.98 glucose; pH 7.4, aerated with
95% O2 and 5% CO2 for 20 min before use). The cere-
bellum and brain stem were removed and the hemi-
spheres separated. Two parallel cuts, rostral and ventral,
were made at a ≈ 60º angle from the midline. A blocked
hemisphere was mounted using super glue and sectioned
transversely at 350 − 400 μm using a tissue slicer. The
hippocampal-EC region was separated gently from slices
and transferred to an incubation chamber containing
carbogenated ACSF for 2 h before transfer to a record-
ing chamber. The slice was secured with a slice anchorand perfused with carbogenated ACSF at 2 ml/min for
recording.
Before electrophysiological recording using a MED-64
planar microelectrode array, [46], slices were photo-
graphed with a CCD camera (DP-70, OLYMPUS, Japan).
The MED-P530A probe was connected to a 64-channel
amplifier. Each probe corresponds to an amplifier
channel and can deliver stimuli as well as record elec-
trophysiological signals. One of the electrodes over the
perforant pathway (PP) was used for stimulation. The
electrode near the hippocampal sulcus producing the
largest field excitatory postsynaptic potentials (fEPSPs)
was chosen as the stimulating site for LTP experiments.
A biphasic square-wave pulse (0.1 Hz, 0.2 ms, 10 −
199 μA) was delivered to evoke fEPSPs over the entire
region underneath the array. Two input/output curves
(fEPSP amplitude against stimulus intensity and fEPSP
slope against stimulus intensity) were constructed from
the means of five stimulus pulses at seven intensities
(30, 60, 90, 120, 150, 180, and 199 μA). For induction of
LTP, the stimulation intensity was set to elicit 50% of the
maximum fEPSP according to the input/output curves.
Following 30 min of stable baseline recording, LTP was
induced by 10 trains, each comprised of 4 pulses at
100 Hz, with 200-ms inter-train intervals (θ burst stimu-
lation, TBS). Post-TBS fEPSPs were recorded every
10 min for another 2 h. Sampling rate was 20 kHz and
the signals were low-pass filtered at 0.1 Hz. All the
stimulating protocols were generated by software.
Open field test
To assess spontaneous locomotor activity, rats were
tested in an open field (JLBehv-LAG-4, Shanghai Jiliang
Software Technology) [47]. Each rat was gently placed in
the center of the open field and allowed to explore
freely. The spontaneous motor activity of 4 rats was
simultaneously monitored using an automated camera-
based computer tracking system. At the end of the test,
the open field was cleaned with 75% ethyl alcohol. The
open field was located in a room (22 − 26°C) isolated
from sound and unintentional interruptions and lit by
consistent background lighting. Each trial was conducted
between 8:00 − 11:00 am and recorded for later analysis.
Statistical analysis
Data are presented as mean ± S.E.M. Group means were
compared using Mann-Whitney U-tests (for non-para-
metric data sets), paired-sample t-tests (for normally
distributed data sets), and one-way analysis of variance
(ANOVA) (for multi-group comparisons) with Fisher’s
Protected Least Significant Difference (PLSD) test for
post hoc pair-wise comparisons. All calculations were
performed with SPSS software (SPSS Inc., Chicago, Il). A
P < 0.05 was considered statistically significant.
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